Ardelyx Inc ARDX
News
-
Faruqi & Faruqi Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024 - ARDX
-
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit
-
October 15, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ARDX
-
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Nano Ardelyx, Inc. (ARDX) Investors
-
Investors in Ardelyx, Inc. Should Contact The Gross Law Firm Before October 15, 2024 to Discuss Your Rights - ARDX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX
-
ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm
-
Levi & Korsinsky Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ARDX
Trading Information
- Previous Close Price
- $6.36
- Day Range
- $6.39–7.18
- 52-Week Range
- $3.16–10.13
- Bid/Ask
- $6.70 / $6.76
- Market Cap
- $1.57 Bil
- Volume/Avg
- 6.5 Mil / 4.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.31
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 267
- Website
- https://www.ardelyx.com
Comparables
Valuation
|
Metric
|
ARDX
|
EWTX
|
CTNM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 10.65 | 4.79 | 2.23 |
Price/Sales | 7.31 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ARDX
EWTX
CTNM
Financial Strength
|
Metric
|
ARDX
|
EWTX
|
CTNM
|
|---|---|---|---|
Quick Ratio | 3.57 | 29.79 | 58.48 |
Current Ratio | 4.21 | 30.24 | 58.92 |
Interest Coverage | −3.67 | — | — |
Quick Ratio
ARDX
EWTX
CTNM
Profitability
|
Metric
|
ARDX
|
EWTX
|
CTNM
|
|---|---|---|---|
Return on Assets (Normalized) | −15.08% | −23.23% | −18.15% |
Return on Equity (Normalized) | −28.73% | −24.43% | −871.68% |
Return on Invested Capital (Normalized) | −15.20% | −29.19% | −892.99% |
Return on Assets
ARDX
EWTX
CTNM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rrnymcgp | Zlmb | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xlggdgys | Fydtlc | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Kqqbvnf | Mkvym | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gtwplqfks | Mhpskhp | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Npbvwfxs | Pmfw | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Wtshjkxn | Mvq | $28.1 Bil | |||
| Moderna Inc
MRNA
| Ygtgsmhg | Hqdgb | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Dpmpvjgth | Wmg | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Sqwrxys | Jsgqmm | $13.4 Bil | |||
| Incyte Corp
INCY
| Mcfbkhq | Nrlgvm | $12.7 Bil |
United States